CIS Display™️: a fully in vitro platform for enhancing small-format discovery

Today, there are many display technologies in the market. The yeast and mammalian display, for example, are good for complex scaffolds, but they struggle with displaying large libraries. In this video, Lurdes Rodrigues Duarte, Director of R&D at Isogenica, explains why we use CIS Display™️ to get full use of our VHH libraries and how this technology works.

Learn More about CIS Display™️

Read More Research-Focused Blog Posts

Building the next generation of precision oncology medicines

Biologic therapies have reshaped oncology, but they come with real limitations. Traditional monoclonal antibodies are large, complex molecules that can struggle with tumor penetration, slow development timelines, and costly manufacturing. In a field where time is critical and healthcare budgets are under increasing pressure, these constraints can hold back promising innovations. Read the article.

Avoiding Freedom-to-Operate Pitfalls in Antibody Discovery

Conventional immunization-based discovery techniques frequently result in overlapping sequences with intellectual property (IP) concerns, due to the high number of antibody sequences already patented. These limitations can restrict opportunities for development, increase legal uncertainty, and reduce commercial viability.

Comparing Risk in Synthetic vs Immune-based Discovery: Why Synthetic VHH Antibodies are the Future of Antibody Discovery

This case study delves into the development of anti-LRP6 VHH inhibitors that overcome these challenges. Isogenica’s VHH technology offers hope for more effective therapies targeting Wnt-related cancers.

Anti-LRP6 VHHs: Precision Targeting of the Wnt Pathway for Cancer Therapy

Solid Tumour Targeting – VHH antibodies as building blocks for advanced cancer therapies

Cancer continues to pose a significant challenge in the realm of biomedical research, particularly with respect to solid tumors, which constitute over 90% of adult cancer cases.But what makes solid tumors so challenging? And what solutions are available to overcome...

Unlocking Affordable Biologics: VHH Antibodies in Baker’s Yeast

The production of traditional IgG monoclonal antibodies has long been hindered by their complexity. These molecules require complex and costly manufacturing processes, with estimated production costs ranging from $95 to $200 per gram. As well as contributing to issues...